Program
Nalbuphine
Also written as “NAL ER”, “nalbuphine HCl ER” and “Nalbuphine Hydrochloride Injection”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Prurigo · Pruritus · Chronic Cough · Opioid-Related Disorders, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Trevi Therapeutics | 173 open or running | phase 3since May 17, 2014 | May 17, 2014 | Aug 2027phase 3 · NCT07868419 |
| Lumosa Therapeutics | 10 open or running | phase 1since May 13, 2015 | May 13, 2015 | none ahead |
| Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical | 10 open or running | phase 3since Apr 1, 2025 | Apr 1, 2025 | none ahead |
| Yung Shin Pharm. Ind. | 10 open or running | phase 4since Jan 27, 2019 | Jan 27, 2019 | none ahead |
Also a collaborator on its studies: parexel and davita-clinical-research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since May 17, 2014.
- Feb 13, 2015Phase 1 study in Uremic PruritusTrevi Therapeutics · NCT02373215 · 22 enrolled
- May 13, 2015Lumosa Therapeutics's first study: phase 1 study in PainNew to Lumosa TherapeuticsLumosa Therapeutics · NCT02446301 · 12 enrolled · Taiwan
- Mar 22, 2018Phase 3 study in Prurigo NodularisTrevi Therapeutics · NCT03497975 · 353 enrolled · United States, Austria, France and more
- Jan 27, 2019Yung Shin Pharm. Ind.'s first study: phase 4 study in Pain, PostoperativeNew to Yung Shin Pharm. Ind.Yung Shin Pharm. Ind. · NCT03826316 · 14 enrolled · Taiwan
- May 30, 20192 phase 1 studiesTrevi Therapeutics · NCT04020016, NCT04018664
- Jul 11, 2019Phase 2 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT04030026 · 42 enrolled · United Kingdom
- Jul 7, 20232 phase 2 studiesTrevi Therapeutics · NCT05964335, NCT05962151
- Apr 1, 2025Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical's first study: phase 3 study in Postoperative AnalgesiaNew to Yangtze River Pharmaceutical Group Jiangsu Zilong PharmaceuticalYangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical · NCT06949852 · 289 enrolled · China
- May 29, 2025Phase 1 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07036029 · 9 enrolled · United States, United Kingdom
- Jun 3, 2025Phase 1 study in Healthy ParticipantsTrevi Therapeutics · NCT07015398 · 132 enrolled · United States
- Mar 17, 2026Phase 1 study in Healthy ParticipantsTrevi Therapeutics · NCT07487740 · 60 enrolled · United States
- Jun 22, 2026Phase 2 study in Chronic CoughTrevi Therapeutics · NCT07671924 · 100 planned · Canada, United Kingdom
- Jun 22, 2026Phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07671911 · 306 planned · United States
- Oct 5, 2026Phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07868419 · 201 planned · United States
Ahead
- Aug 2027Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07868419
- Sep 2027Primary completion: phase 2 study in Chronic CoughTrevi Therapeutics · NCT07671924
- Jun 2028Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisTrevi Therapeutics · NCT07671911
TargetBeta
“Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07868419Idiopathic Pulmonary Fibrosis · United States | 3 | Recruiting | Trevi Therapeutics | Aug 2027 | 201 |
| NCT07671924Chronic Cough · Canada, United Kingdom | 2 | Recruiting | Trevi Therapeutics | Sep 2027 | 100 |
| NCT07671911Idiopathic Pulmonary Fibrosis · United States | 3 | Recruiting | Trevi Therapeutics | Jun 2028 | 306 |
| NCT07487740Healthy Participants · United States | 1 | Completed | Trevi Therapeutics | May 11, 2026 | 60 |
| NCT07015398Healthy Participants · United States | 1 | Completed | Trevi Therapeutics | Sep 12, 2025 | 132 |
| NCT07036029Idiopathic Pulmonary Fibrosis · United States, United Kingdom | 1 | Completed | Trevi Therapeutics | Jun 30, 2026 | 9 |
| NCT06949852Postoperative Analgesia · China | 3 | Completed | Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical | Jul 8, 2025 | 289 |
| NCT05964335Idiopathic Pulmonary Fibrosis · Australia, Canada, Chile and more | 2 | Completed | Trevi Therapeutics | Apr 24, 2025 | 165 |
| NCT05962151Chronic Cough · Canada, United Kingdom | 2 | Completed | Trevi Therapeutics | Jan 6, 2025 | 66 |
| NCT04030026Idiopathic Pulmonary Fibrosis · United Kingdom | 2 | Completed | Trevi Therapeutics | May 27, 2022 | 42 |
| NCT04020016Hepatic Impairment · United States | 1 | Completed | Trevi Therapeutics | Feb 5, 2020 | 28 |
| NCT04018664Opioid-Related Disorders · Canada | 1 | Completed | Trevi Therapeutics | Dec 3, 2018 | 56 |
| NCT03826316Pain, Postoperative · Taiwan | 4 | Completed | Yung Shin Pharm. Ind. | Nov 22, 2018 | 14 |
| NCT03497975Prurigo Nodularis · United States, Austria, France and more | 3 | Completed | Trevi Therapeutics | May 10, 2022 | 353 |
| NCT02446301Pain · Taiwan | 1 | Completed | Lumosa Therapeutics | Apr 2015 | 12 |
| NCT02373215Uremic Pruritus | 1 | Completed | Trevi Therapeutics | Nov 2013 | 22 |
| NCT02174432Prurigo · Germany | 3 | Completed | Trevi Therapeutics | Sep 3, 2017 | 36 |
| NCT02174419Prurigo · United States, Germany, Poland | 3 | Completed | Trevi Therapeutics | Aug 2016 | 62 |
| NCT02143973Pruritus · United States | 3 | Completed | Trevi Therapeutics | Jan 2016 | 167 |
| NCT02143648Pruritus · United States, Poland, Romania | 3 | Completed | Trevi Therapeutics | Jul 2015 | 373 |
How it is read
Names in the registry
- “NAL ER”, 11 entries
- “nalbuphine HCl ER”, 2 entries
- “Nalbuphine Hydrochloride Injection”, 1 entry
- “Nalbuphine ER”, 1 entry
- “Nalbuphine ER Tablets”, 1 entry
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 5 studies
- Prurigo, 3 studies
- Pruritus, 3 studies
- Chronic Cough, 2 studies
- Opioid-Related Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.